Literature DB >> 12018383

Laboratory surveillance for wild poliovirus and vaccine-derived poliovirus, 2000-2001.

.   

Abstract

After the 1988 World Health Assembly resolution to eradicate poliomyelitis, the Global Laboratory Network for Poliomyelitis Eradication (the laboratory network) was established by the World Health Organization (WHO). The laboratory network is one component of the international surveillance system for detecting polio through notification of cases of acute flaccid paralysis (AFP). As progress is made in eradicating polio worldwide, the laboratory network provides critical virologic evidence about where poliovirus is circulating as a guide to supplementary vaccination activities aimed at interrupting transmission. This report summarizes the laboratory data for documenting the decline in wild poliovirus transmission and the occurrence of vaccine-derived polioviruses and highlights the expanding role of the laboratory network in global polio eradication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018383

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  7 in total

1.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002.

Authors:  Y Manor; S Blomqvist; D Sofer; J Alfandari; T Halmut; B Abramovitz; E Mendelson; L M Shulman
Journal:  Appl Environ Microbiol       Date:  2007-07-27       Impact factor: 4.792

4.  Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria.

Authors:  A O Adedeji; I O Okonko; F D Adu
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

5.  Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates.

Authors:  Lester M Shulman; Danit Sofer; Yossi Manor; Ella Mendelson; Jean Balanant; Anna Laura Salvati; Francis Delpeyroux; Lucia Fiore
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

6.  Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations.

Authors:  Lester M Shulman; Yossi Manor; Danit Sofer; Rachel Handsher; Tiberio Swartz; Francis Delpeyroux; Ella Mendelson
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

7.  Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016.

Authors:  Merav Weil; Lester M Shulman; Sophia Heiman; Tali Stauber; Jacqueline Alfandari; Leah Weiss; Ilana Silberstein; Viki Indenbaum; Ella Mendelson; Danit Sofer
Journal:  Euro Surveill       Date:  2016-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.